SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wedne ...

An updated edition of the Jan. 6, 2026, article.Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.It is important to distinguish between genetics and genomics. Genetics focuses on individual genes and their functions, whereas genomics primarily ai ...

Core Insights - Sana Biotechnology, Inc. has appointed Brian Piper as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical financial and operational expertise [1][2] - The company anticipates generating initial clinical data for its therapies SC451 and SG293 within the next 12-18 months, which are aimed at treating type 1 diabetes and B-cell related diseases, respectively [2] - The leadership of Mr. Piper is expected to be critical in advancing the company's portfolio and optimizing long-term value creation [2][3] Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, with a vision to repair and control genes and replace missing or damaged cells [4] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA [4]

Core Insights - Shares of Sana Biotechnology, Inc. (SANA) have nearly tripled from their recent lows in early April, primarily driven by positive data from a type 1 diabetes patient who received a precursor treatment [1] Group 1: Company Performance - The significant increase in SANA's share price indicates strong market interest and investor confidence, likely fueled by promising clinical data [1] - The company is involved in engineered cell therapies, which are gaining traction in the biotech sector [1] Group 2: Analyst Commentary - Bret Jensen, a market analyst with over 13 years of experience, leads The Biotech Forum, which focuses on high beta biotech stocks with potential for large returns [1] - The Biotech Forum offers a model portfolio of 12-20 high upside biotech stocks, along with live discussions and weekly updates on market commentary and portfolio performance [1]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Sana Biotechnology (SANA) - Sana Biotechnology currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4] - The stock has shown a price increase of 5.46% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 1.19% [6] - Over the past month, SANA's shares increased by 13.02%, significantly higher than the industry's 0.21% performance [6] - In the last quarter, SANA shares rose by 13.58%, and over the past year, they gained 31.81%, while the S&P 500 only moved 1.27% and 16.57%, respectively [7] Trading Volume - SANA's average 20-day trading volume is 2,416,938 shares, indicating a bullish sign when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for SANA has increased, raising the consensus estimate from -$0.87 to -$0.86 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [10] Conclusion - Considering the positive momentum indicators and earnings outlook, SANA is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Core Viewpoint - Sana Biotechnology (SANA) has shown a significant price increase of 10.4% over the past four weeks, with a mean price target of $8.71 indicating a potential upside of 74.2% from its current price of $5 [1]. Price Targets - The average price target consists of seven estimates ranging from a low of $6.00 to a high of $12.00, with a standard deviation of $2.43, suggesting a variability in analyst estimates [2]. - The lowest estimate indicates a 20% increase from the current price, while the highest suggests a 140% upside potential [2]. Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about SANA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 0.6% increase over the last 30 days [4][12]. - The Zacks Consensus Estimate for the current year has improved, with one estimate moving higher and no negative revisions [12]. - SANA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are often sought after by investors, their reliability has been questioned, as they can mislead rather than guide investment decisions [3][7]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9].

Core Insights - Sana Biotechnology, Inc. focuses on developing ex vivo hypoimmune therapy and in vivo fusogen-based delivery systems to treat cancer and autoimmune diseases [1] Company Overview - The company is engaged in innovative biotechnological solutions aimed at addressing significant medical challenges in oncology and autoimmune disorders [1] Technology and Innovation - Sana's ex vivo platform is designed to enhance therapeutic efficacy by utilizing hypoimmune strategies, which may improve patient outcomes in complex diseases [1]

Company Overview - The company, Sana, was founded with two main goals: to overcome allogeneic rejection in cell therapy and to effectively deliver genetic payloads to cells [3][4]. Industry Challenges - Allogeneic rejection occurs when a patient's body rejects foreign cells, which poses a significant challenge for making cell therapy universally available [3]. - Delivering genetic material into cells remains a complex task, despite advancements in genome manipulation in laboratory settings [4]. Progress and Developments - The company has reported making significant progress in addressing the challenges associated with allogeneic rejection and the delivery of genetic payloads [4].

Summary of Sana Biotechnology FY Conference Call Company Overview - **Company**: Sana Biotechnology (NasdaqGS:SANA) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 14, 2026 - **Presenter**: Steve Harr, President and CEO Core Industry Focus - **Industry**: Biotechnology, specifically in cell therapy and gene editing - **Target Disease**: Type 1 diabetes and potential applications in blood cancers and autoimmune diseases Key Points and Arguments Goals and Progress - **Main Goals**: - Overcome allogeneic rejection in cell therapy to make it universally available - Develop effective delivery methods for genetic payloads to cells [2][3] - **Focus Area**: Type 1 diabetes, a significant unmet medical need with high demand for better treatment options [3][9] Achievements - **Cell Transplantation**: Successfully demonstrated the ability to transplant cells that evade the immune system [4] - **Master Cell Bank**: Established a master cell bank for consistent production of pancreatic beta cells [4][28] - **Regulatory Engagement**: Engaged with global regulators to align on future plans, including filing an Investigational New Drug (IND) application [4][29] Clinical Development - **Phase One Study**: Plans to file IND and begin Phase One study within the year, aiming for quick proof of concept regarding immune evasion and functional insulin production [4][30] - **Patient Outcomes**: A patient who received the therapy has shown no adverse events and continued insulin production for over a year [16][21] Scientific Insights - **Mechanism of Action**: - Knocking out MHC class I and II to prevent immune rejection, combined with overexpression of CD47 to evade both adaptive and innate immunity [13][14] - Evidence of survival and function of transplanted cells through C-peptide levels and PET MRI scans [17][21] Market Potential - **Unmet Need**: Curing type 1 diabetes could equate to curing both HIV and multiple sclerosis in the U.S., highlighting the vast market potential [9] - **Scalability**: The goal is to create a scalable therapy that can treat millions of patients, with a focus on manufacturing efficiency [28][58] Future Directions - **In Vivo CAR T Cells**: Development of a best-in-class in vivo CAR T platform, with plans to initiate trials in cancer and autoimmune diseases [43][60] - **Partnership Strategy**: Considering partnerships to accelerate development in competitive areas like B cell cancers and autoimmune diseases [60] Regulatory and Manufacturing Challenges - **Regulatory Complexity**: Navigating the complexities of novel immunology, gene editing, and stem cell biology with regulators [51] - **Manufacturing Scale**: Challenges in scaling production from Phase One to commercial levels, focusing on maintaining genomic stability and purity [45][47] Investment and Financial Outlook - **Investment Needs**: Significant investment required for manufacturing scale-up and clinical development, with ongoing financial commitments expected [56][58] Additional Important Insights - **Patient Population for Trials**: Initial trials will focus on adults with type 1 diabetes, with plans to expand to younger populations as data is gathered [52][53] - **Global Reach**: The Phase One study will not be limited to the U.S. but will include other geographies [54] This summary encapsulates the key points discussed during the conference call, highlighting Sana Biotechnology's strategic focus, achievements, and future plans in the biotechnology sector.

Corporate Presentation January 2026 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects ...